Disclosure of Conflicts of Interest – Prof. Stefan Symeonides

This is a disclosure report regarding direct/indirect conflicts of interest of a financial, functional or any other nature related to commercial and non-commercial organizations.

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

• No financial interests in any commercial pharmaceutical entity
• No personal gain from any of the below unless highlighted in bold
• • Educational & travel:
    • Ipsen (6/17, 6/18, 9/19, 9/21, 9/22), EUSA (6/21, 6/22), BioNTech (11/21), MSD (2/22)
  • Consultancy (my institution):
    • Nil current
  • Scientific advisory role (my institution, unless highlighted in bold):
    • Duke Street Bio (22/3/22 – )
    • Eisai (18/3/19, 20/12/22)
    • Ellipses (11/4/18 – )
    • Eugit Therapeutics (10/22 -)
    • Exscientia (13/8/23 -)
    • Grey Wolf Therapeutics (25/5/23 – )
    • MSD (10/5/19, 3/7/20, 4/3/21, 6/7/21, 7/7/21, 15/10/21, 17/3/22, 15/12/22)
  • Speaker (my institution, unless highlighted in bold):
    • Eisai (31/10/22)
    • Ipsen (26/10/21 clinicians; 6/11/21, 18/3/22, 30/3/23 & 21/9/23 non-promotional educational, unrelated to company’s products)
    • MSD (31/3/22 internal MSD, 23/5/22 internal MSD)
  • Research funding (my institution):
    • MSD (trial funding and drug supply, trials staff) (6/15-)
    • Verastem (trial funding and drug supply) (6/15-)
  • Independent Data / Safety Monitoring (my institution, unless highlighted in bold):
    • Exscientia (13/8/23 -)
    • WCG (16/2/23 – )
    • Grey Wolf Therapeutics (25/5/23 – )
  • Research collaboration (as PI/CI):
    • Pharmaceutical companies
      • MSD (MK3475-564 13/2/17, MK3475-U03a/b), BioNTech (5/11/19), Boston Pharmaceuticals (2/11/17 – 12/4/21), Sierra Oncology (SRA737-01, 12/4/17-12/19), Agalimmune/BioLineRx (1/5/19), Nucana (13/3/19), Nouscom (26/4/21), Sapience (18/3/20), Roche (14/6/21), Incyte (26/10/21), Scancell (ModiFY 22/4/22), Medannex (4/8/23). In set-up: AZ, Grey Wolf Therapeutics, Nuvectis, Salubris Bio, Seagen, TargImmune
      • Co-I
        • MSD (MK3475-427, 005), Anicca, ARCADIAN, Ipsen (CaboPoint 18/2/21), CALYPSO, CAPER, CAReS, CellCentric (9/12/20), Eisai (CLEAR 20/6/17), LY314, MITRE, NAXIVA, PRISM, RAMPART, A-PREDICT, STAR, TARGET, IMAGINE
      • CROs
        • TMC Pharma, Chiltern, Clinipace, Precision for Medicine, ICON, PharmOlam

 

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

• University of Edinburgh – Senior Clinical Lecturer in Experimental Cancer Medicine
  • 24 funded hours per week
• NHS – Consultant Medical Oncologist (Edinburgh Cancer Centre)
  • 4 funded hours per week (as South East Scotland Cancer Research Network Lead); additional on-call and unfunded work (including renal cancer, registrar teaching, clinical care of trials patients)
• CRUK – Medical Advisor (Centre for Drug Development)
  • 20 funded hours per week
• Collaborating universities (directly linked by research funding/trial funding)
  • University of Glasgow (inc Glasgow CRUK CTU), University of Southampton, University of Leicester, Queens University Belfast, Institute of Cancer Research London

 

Last updated on 22 February 2024